Skip to main content
Better together.
Fred Hutch
Seattle Children's
UW Medicine
Enter the terms you wish to search for.

Related Nav

  • Contact Us
  • Donate and Volunteer
  • For Healthcare Professionals

Main navigation

  • New Patients
    • Why Seek Treatment at SCCA?
    • Preparing for Your First Visit
    • Locations
    • Transportation
    • Insurance Coverage and Bills
    • Services and Support
    • Patient Stories
  • Diseases and Treatments
    • Treatment Options
    • Clinical Trials
    • During Your Treatment
    • Coping with Side Effects
    • Palliative Care
    • Self Care
  • After Treatment
    • Coping with After Effects
    • Survivor Health Tips
    • Survivorship Events
  • Resources
    • Resources for Caregivers
    • For Children and Teens
    • Emotional and Spiritual Support
    • Health and Nutrition
    • Services and Support
    • Medical Record Request
Resources for Patients and Caregiviers
Your support team includes nutritionists, emotional support, caregiver resources, and so much more.
Learn more
Real Stories from Real Patients
Our patients share their stories of hope, care and outcomes
Learn more
Help Us Help Future Patients
Our patient advisory board helps us continually improve the patient experience. Join us.
Learn more
Caresi
Patient care app
Caresi® is a personal health app, created by SCCA for you, our patient. With the app, view your schedule, access lab results, contact care teams and review resources.
Learn more
Sunshine Pegues
David Dunnington
Stephanie Florence
Denny Partosa
Marc Mutz
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin followed by Maintenance Rucaparib in Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with Homologous Recombination DNA Repair Deficiency
Investigator

Heather H. Cheng

Heather
H.
Cheng
MD, PhD
Trial Phase
Phase II
Study Number
NCT03442556
Local Study ID
9841
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
PRIMARY OBJECTIVES: I. To determine radiographic progression free survival with 4 cycles of docetaxel with carboplatin followed by maintenance rucaparib camsylate (rucaparib) in the treatment of patients with metastatic castration resistant prostate cancer with homologous recombination DNA repair deficiency. SECONDARY OBJECTIVES: I. To assess maximal prostate-specific antigen (PSA) response to induction docetaxel and carboplatin. II. To assess PSA response to switch maintenance with rucaparib. III. To assess PSA response duration to docetaxel and carboplatin followed by switch maintenance with rucaparib. IV. To assess response of measurable disease. OUTLINE: INDUCTION: Patients receive docetaxel intravenously (IV) and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive rucaparib camsylate orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Trial Eligibility
•Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information
•Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
•Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy; patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy
•Castration resistant prostate cancer as defined by serum testosterone
•Presence of metastatic disease on bone or computed tomography (CT) scan
?Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
?Bone disease on bone scan

•Prior therapy with sipuleucel-T, abiraterone, enzalutamide, docetaxel, and/or cabazitaxel; there is no limit to the number of prior treatment regimens, so long as prior therapy does not include platinum chemotherapy or a PARP inhibitor
•Eastern Cooperative Oncology Group (ECOG) performance status of = •Life expectancy >= 12 weeks

•No prior malignancy is allowed except:
?Adequately treated basal cell or squamous cell skin cancer or
?In situ carcinoma of any site or
?Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)


•Documented evidence of at least ONE or MORE of the following:
?Biallelic inactivation of genes involved in homologous recombination repair in the tumor
?Biallelic inactivation of other genes involved in homologous DNA recombination repair in the tumor may be included at investigator's discretion
?Homologous recombination repair deficiency by genomic signature in the tumor
?Clearly pathogenic or likely pathogenic germline mutation in BRCA2, BRCA1 and/or ATM
?(Note: the following are not alone sufficient for eligibility and require additional criteria to be met: germline variant of uncertain significance in BRCA1, BRCA2 and/or ATM; germline mutations in other HR genes)

•Within 14 days of first dose of study drug: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
•Within 14 days of first dose of study drug: Platelets > 100 x 10^9/L
•Within 14 days of first dose of study drug: Hemoglobin >= 9 g/dL
•Within 14 days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = •Within 14 days of first dose of study drug: Bilirubin = •Within 14 days of first dose of study drug: Serum creatinine == 45 mL/min using the Cockcroft Gault formula
Other eligibility criteria may apply.
Trial Exclusions
•Currently receiving active therapy for other neoplastic disorders
•Symptomatic and/or untreated central nervous system (CNS) metastases; patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks
•Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease
•Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of •Treatment with an investigational therapeutic drug within 30 days of cycle 1
•Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)
•Prior therapy with a platinum chemotherapy (e.g. cisplatin, carboplatin, oxaliplatin)
•Active, ongoing toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher) from prior therapy
•Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding and/or giving of informed consent
•Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
•Any condition(s), medical or otherwise, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained
Other exclusion criteria may apply.
Trial Keywords
Prostate Cancer
See this trial at ClinicalTrials.gov

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.

Patient Guide to Clinical Trials
Locations
Request an Appointment
Find a Physician

Connect With Us

  • Contact Us
  • Request an Appointment
  • Careers
  • Referring Doctors
  • Phone Directory
  • Press and News
  • Social Media
  • Community Benefit
Follow Us
http://twitter.com/SeattleCCA
http://www.facebook.com/SeattleCancerCareAlliance
http://www.youtube.com/user/SeattleCancerCare
http://www.sccablog.org/
https://www.nccn.org/Members/Profiles/Default.aspx?MemberId=8
https://www.qualitycheck.org/quality-report/?bsnid=328340

SCCA Locations

  • South Lake Union
  • SCCA Peninsula
  • UW Medical Center
  • EvergreenHealth
  • UW Medicine’s Northwest Hospital
  • SCCA Proton Therapy Center
  • Seattle Children's

Seattle Cancer Care Alliance

825 Eastlake Ave. E

PO Box 19023

Seattle, WA 98109­-1023

©2004-2019 Seattle Cancer Care Alliance. All Rights Reserved.

footer legal links

  • SCCA Links
  • Privacy Policy
  • Public Care Policy
  • Disclaimer
  • Financial Assistance
  • Notice of Nondiscrimination

Seattle Cancer Care Alliance is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read EEO is the Law poster here. 

Better together.
Fred Hutch
Seattle Children's
UW Medicine